- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03358823
Study on the Brain Network of Angelman Syndrome
April 23, 2021 updated by: Yi Wang, Fudan University
Study on the Brain Network of Angelman Syndrome Based on Multi-modal Brain Image and Neural-EEG Data
The aims of study on Angelman syndrome:
- Establish the Angelman syndrome database
- Explore the brain Network of Angelman Syndrome Based on Multi-modal Brain Image and Neural-EEG Data
Study Overview
Status
Completed
Conditions
Detailed Description
- The participants recruitment: from Chinese Angelman Syndrome Patients group (Angelhome : angelman225@126.com) and Children's Hospital of Fudan University.
- Fistly all participants had clinically and molecularly confirmed as Angelman syndrome . All participants should entry the online questionnaries and carified by telephone or on site . All the information will be recorded in the Angelman syndrome database. Investigators will analyze and summarize the relationship of phenotype and genotype(n=200).
- Participants who assigned the informed consent and will undergo the brain MRI inspection and Neural-EEG recording in the Children's Hospital of Fudan University. The healthy age- and sex-matched control participants will enrolled in the same hospital. The Investigators will explore the brain morphology and electrophysiological alterations and for Angelman syndrome (AS) children among the different genotypes(n=200).
Study Type
Observational
Enrollment (Actual)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200232
- Children's Hospital of Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The patients of Angelman syndrome meet the clinical and genetic diagnosis criteria
Description
Inclusion Criteria:
- Clinical and molecular diagnosis of Angelman syndrome.
- Agreed and completed the MRI scan and EEG-recording by using oral chloral hydrate.
Exclusion Criteria:
- Reject MRI scan and EEG-recording by using oral chloral hydrate or unable to complete the scan.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Angelman syndrome
Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011).
all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including
maternal deletions involving chromosome 15q11.2-q13;paternal
uniparental disomy of 15q11.2-q13;imprinting
defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Angelman syndrome databas; Brain Network of Angelman syndrome
Time Frame: 0-18 years old
|
|
0-18 years old
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yi Wang, Dr., Children's Hospital of Fudan University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Aghakhanyan G, Bonanni P, Randazzo G, Nappi S, Tessarotto F, De Martin L, Frijia F, De Marchi D, De Masi F, Kuppers B, Lombardo F, Caramella D, Montanaro D. From Cortical and Subcortical Grey Matter Abnormalities to Neurobehavioral Phenotype of Angelman Syndrome: A Voxel-Based Morphometry Study. PLoS One. 2016 Sep 14;11(9):e0162817. doi: 10.1371/journal.pone.0162817. eCollection 2016.
- Tiwari VN, Jeong JW, Wilson BJ, Behen ME, Chugani HT, Sundaram SK. Relationship between aberrant brain connectivity and clinical features in Angelman Syndrome: a new method using tract based spatial statistics of DTI color-coded orientation maps. Neuroimage. 2012 Jan 2;59(1):349-55. doi: 10.1016/j.neuroimage.2011.07.067. Epub 2011 Jul 30.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 20, 2017
Primary Completion (ACTUAL)
May 20, 2019
Study Completion (ACTUAL)
May 20, 2019
Study Registration Dates
First Submitted
November 25, 2017
First Submitted That Met QC Criteria
November 25, 2017
First Posted (ACTUAL)
December 2, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 26, 2021
Last Update Submitted That Met QC Criteria
April 23, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016YFC0904400
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angelman Syndrome
-
Ovid Therapeutics Inc.CompletedPrimary Disease or Condition Being Studied: Angelman Syndrome (AS)United States, Australia, Germany, Israel, Netherlands
-
University of OxfordHoffmann-La Roche; Foundation for Angelman Syndrome Therapeutics UKRecruiting
-
Fondazione per la Ricerca Ospedale MaggioreCompleted
-
Ovid Therapeutics Inc.CompletedAngelman SyndromeUnited States, Israel
-
Boston Children's HospitalCompletedAngelman SyndromeUnited States
-
Puerta de Hierro University HospitalParc Taulí Hospital UniversitariRecruiting
-
Foundation for Angelman Syndrome Therapeutics,...Queensland University of TechnologyRecruiting
-
The Emmes Company, LLCBoston Children's Hospital; Ionis Pharmaceuticals, Inc.CompletedAngelman SyndromeUnited States
-
University of Colorado, DenverCompleted
-
Hoffmann-La RocheActive, not recruitingAngelman SyndromeUnited States, Spain, Netherlands, Italy